Protein degradation field turns red hot as Bristol Myers signs up for another multibillion-dollar pact

Rupert Vessey, Bristol Myers Squibb's President of Research and Early Development

May 10, 2022 12:37 PM EDTUpdated May 11, 03:34 AM

Protein degradation field turns red hot as Bristol Myers signs up for another multibillion-dollar pact

John Carroll

Editor & Founder

A new season of protein degradation deals is upon us.

Just days after Rupert Vessey anted up on a $1.55 billion deal to advance new discovery work on protein therapeutic degraders with the Scottish biotech Amphista, he’s jumped back with a $5 billion pact on another protein degradation effort with the developers at Evotec in Europe as the field continues to heat up with multiple alliances.

This time Vessey and his crew are coming with a hefty $200 million upfront to expand on a deal that dates back to 2018, looking to build a pipeline of molecular glue degraders — one of the primary approaches in the field.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.

May 28, 2022 06:00 AM EDT

Weekly

Biomarker 'roadmaps' and the future of cancer R&D; Curtain raises on #ASCO22; Pfizer, Novartis tackle drug access; and more

Amber Tong

Senior Editor

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

While this was not a week for earth-shattering news, there were certainly a lot of interesting tidbits. If you found this recap helpful, please recommend it to your friends and colleagues. We’ll see you on the other side of the long weekend.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.

May 27, 2022 07:40 AM EDT

R&D

Keeping pressure on Amgen, Mirati draws mixed reviews on latest cut of KRAS data

Amber Tong

Senior Editor

As the close runner-up to Amgen’s Lumakras in the KRAS race, any data cut from Mirati’s adagrasib continues to draw scrutiny from analysts. And the latest batch of numbers from ASCO is a decidedly mixed bag.

While a quick comparison suggests that adagrasib spurred slightly more responses and led to a longer overall survival than Lumakras among a group of non-small cell lung cancer patients, its duration of response appears shorter and the safety profile continues to spark concern.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.

Nassim Usman, Catalyst Biosciences CEO

May 27, 2022 09:51 AM EDTUpdated 10:11 AM

Deals

After $60M Vertex deal, group of Catalyst shareholders claims biotech could’ve sold assets three years ago

Kyle LaHucik

Associate Editor

Catalyst Biosciences was down to five employees in March, and the biotech needed to do something after two rounds of layoffs, a nixed collaboration and a culling of its hemophilia program.

In came Vertex, with $60 million to buy up the South San Francisco biotech’s preclinical complement drugs, which target the system that bridges the body’s innate and adaptive immune response and a class most known for Ultomiris and Soliris. The deal includes CB 2782-PEG, the dry AMD drug that Biogen no longer wanted in March.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.

ENDPOINTS CAREERS

Associate Director, Information Scientist, Library & Information Services

Gilead Sciences

Remote

view job offer post your job now

Ann is one of ViiV Healthcare's newest spokespeople as the retired school administrator speaks up about her HIV status.

May 27, 2022 12:54 PM EDT

Pharma

Marketing

GSK's ViiV debuts next evolution in HIV med Dovato campaign with new spokespeople and new message

Beth Snyder Bulik

Senior Editor

When Ann saw the first TV commercials for HIV medicine Dovato, she didn’t see herself represented. So the 74-year-old retired school administrator who’s been living with HIV since 1998, reached out to GSK’s ViiV Healthcare and asked why not?

Now Ann is one of three people starring in ViiV’s latest Dovato campaign called “Detect This.” The next-step evolution in the branded campaign plays on the word “detect” — often used in describing HIV status under control as undetectable — but in this case, uses the word as a directive for people to understand they can use fewer medicines.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.

May 27, 2022 12:42 PM EDT

R&D

Transition to new European clinical trials info system starts slowly

Zachary Brennan

Senior Editor

At the end of January, the European Medicines Agency officially launched its new clinical trials info system (CTIS), although the migration to the new platform has only really just begun, and sponsors have until the end of January 2023 before all initial trial applications must be submitted through CTIS.

Overall, 56 clinical trial applications have been submitted in CTIS during the first 3 months since the launch of the system on Jan. 31, according to new data posted by the EMA. By comparison, about 4,000 new trials are authorized each year across Europe.

May 27, 2022 12:25 PM EDTUpdated 03:47 PM

Pharma

Coronavirus

Manufacturing

Switzerland to destroy over 600,000 expired doses of Moderna Covid vaccine

Tyler Patchen

News Reporter

As concerns related to uptake and distribution continue to linger, Switzerland is among the first countries that plans to destroy hundreds of thousands of expired and unused Covid-19 vaccine doses.

The European country said it plans to destroy more than 600,000 doses of Moderna’s Spikevax Covid-19 vaccine as the doses have reached their expiration date.

However, Moderna CEO Stéphane Bancel told the World Economic Forum in Davos, Switzerland that he’s in the process of throwing 30 million doses in the garbage, exclaiming, “We have a big demand problem.”

Lina Khan, FTC chair (Graeme Jennings/Pool via AP Images)

May 26, 2022 02:10 PM EDTUpdated 04:08 PM

Pharma

Pile-on over PBMs continues with FTC comments and a new bipartisan Senate bill

Zachary Brennan

Senior Editor

More than 500 stakeholders sent comments to the FTC on whether the commission should look further into pharma middlemen, known as PBMs, with many of the commenters calling for more federal oversight.

Similar to the critical open comment period in a deadlocked FTC session last February, pharmacies and pharmacy groups are continuing to call out the lack of transparency among the top 3 PBMs, which control about 80% of the market.

ENDPOINTS CAREERS

Senior Finance Associate

Atlas Venture

Cambridge, MA, USA

view job offer post your job now

Pharma brands are losing their shine with US consumers who are now thinking about the economy and inflation instead of Covid. (Credit: Shutterstock)

May 26, 2022 02:06 PM EDTUpdated 19 hours ago

Pharma

Marketing

Pharma brands fade in annual Harris consumer visibility poll: Moderna drops off and Pfizer dips

Beth Snyder Bulik

Senior Editor

As Covid-19 concerns are fading in the US, so is biopharma visibility. The annual Axios Harris Poll survey to determine and rank the 100 most top-of-mind brands in the US finds Moderna, which was No. 3 last year, not on the list at all for 2022, and Pfizer sinking 37 spots.

However, it’s not that Moderna or Pfizer did anything wrong, it’s just that Americans have moved on to other worries beyond Covid.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.

HHS Secretary Xavier Becerra (Jacquelyn Martin/AP Images)

May 26, 2022 01:59 PM EDTUpdated 04:16 PM

Pharma

FDA+

HHS finishes off Trump-era rule that would've erased basic FDA regs without frequent reviews

Zachary Brennan

Senior Editor

HHS on Thursday finalized its decision to withdraw a rule, proposed just before former President Donald Trump left office, that would’ve caused thousands of HHS and FDA regulations to automatically expire if they weren’t reviewed within two years, and every 10 years thereafter.

The decision follows the filing of a lawsuit last March, in which several nonprofits alleged that the outgoing administration planted “a ticking timebomb” for HHS, essentially forcing it to devote an enormous amount of resources to the unprecedented and infeasible task of reviewing thousands of regulations regularly.